Kane Biotech Inc V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel

<< Previous

Bullboard Posts

Next >>

Comment by KevinOlearyon Nov 15, 2024 2:30pm

35 Views

Post# 36315421

RE:RE:RE:RE:RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel

Yes francois, the holdup in getting to market after the FDA approved the dosage was scheduling with Halo, then shipping to Sweden for canning. Both of those factories have more customers than just KNE, so they had to fit our order in.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China